A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).

开始日期2026-05-01

申办/合作机构

Enlivex Ltd.

[+1]

NCT06748651

/ Recruiting临床1期IIT

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Temporomandibular Joint Osteoarthritis (TMJ-OA)

This study is a single center trial to assess the safety and initial efficacy of intra-articular administration of Allocetra to patients with Temporomandibular Joint Osteoarthritis (TMJ-OA)

开始日期2024-12-15

申办/合作机构

Sheba Medical Center

[+1]

NCT06522035

/ Terminated临床1期

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

This is an open label study to evaluate the safety and initial efficacy of intra-articular administration of Allocetra in patients with Psoriatic Arthritis (PsA).

开始日期2024-08-01

申办/合作机构

Enlivex Ltd.

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的专利（医药）

登录后查看更多信息

项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的文献（医药）

2024-08-19·MILITARY MEDICINE

Apoptotic Cell–Based Therapy for the Modification of the Inflammatory Response to Hemorrhagic Shock

Article

作者: Lutsker, Maya ; Kolben, Yotam ; Mevorach, Dror ; Wagnert-Avraham, Linn ; Aliev, Emil ; Kenig, Ariel ; Kessler, Asa ; Nachman, Dean

ABSTRACT:

Introduction:

Many trauma patients die from hemorrhagic shock in the military and civilian settings. Although two-thirds of hemorrhagic shock victims die of reasons other than exsanguination, such as the consequent cytokine storm, anti-inflammatory therapies failed to be utilized. Apoptotic cell–based treatments enhance innate ability to exert systemic immunomodulation as demonstrated in several clinical applications and hence might present a novel approach in hemorrhagic shock treatment.

Materials and Methods:

Twenty-two rats underwent a pressure-controlled hemorrhagic shock model and followed up for 24 hours. An infusion of apoptotic cells (Allocetra-OTS, Enlivex Therapeutics Ltd, Nes Ziona, Israel) was administered to the treatment group. Hemodynamics, blood counts, biochemistry findings, and cytokine profile were compared to a saline-resuscitated control group.

Results:

The treatment group’s mean arterial pressure decreased from 94.8 mmHg to 28.2 mmHg, resulting in an 8.13 mg/dL increase in lactate and a 1.9 g/L decrease in hemoglobin, similar to the control group. White blood cells and platelets decreased more profoundly in the treatment group. A similar cytokine profile after 24 hours was markedly attenuated in the treatment group 2 hours after bleeding. Levels of pro-inflammatory cytokines such as interleukin (IL)-1a (28.4 pg/mL vs. 179.1 pg/mL), IL-1b (47.4 pg/mL vs. 103.9 pg/mL), IL-6 (526.2 pg/mL vs. 3492 pg/mL), interferon γ (11.4 pg/mL vs. 427.9 pg/mL), and tumor necrosis factor α (19.0 pg/mL vs. 31.7 pg/mL) were profoundly lower in the treatment group.

Conclusion:

In a pressure-control hemorrhagic shock model in rats, apoptotic cell infusion showed preliminary signs of a uniform attenuated cytokine response. Apoptotic cell–based therapies might serve as a novel immunomodulatory therapy for hemorrhagic shock.

Journal of hematology & oncology

Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients

Review

作者: Park, Chandler H ; Joshi, Muskan ; Erick, Timothy K ; Menon, Gayathri P ; Cappelli, Jared ; Sharma, Pushpa ; Wilkerson, William B ; Emmanuel, Nancy ; Leyfman, Yan

Abstract:

Cancer patients, due to their immunocompromised status, are at an increased risk for severe SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage through IL-6-mediated inflammation while stimulating hypoxia, and malignancy promotes hypoxia-induced cellular metabolic alterations leading to cell death, we propose a mechanistic interplay between both conditions that results in an upregulation of IL-6 secretion resulting in enhanced cytokine production and systemic injury. Hypoxia mediated by both conditions results in cell necrosis, dysregulation of oxidative phosphorylation, and mitochondrial dysfunction. This produces free radicals and cytokines that result in systemic inflammatory injury. Hypoxia also catalyzes the breakdown of COX-1 and 2 resulting in bronchoconstriction and pulmonary edema, which further exacerbates tissue hypoxia. Given this disease model, therapeutic options are currently being studied against severe SARS-COV-2. In this study, we review several promising therapies against severe disease supported by clinical trial evidence—including Allocetra, monoclonal antibodies (Tixagevimab–Cilgavimab), peginterferon lambda, Baricitinib, Remdesivir, Sarilumab, Tocilizumab, Anakinra, Bevacizumab, exosomes, and mesenchymal stem cells. Due to the virus’s rapid adaptive evolution and diverse symptomatic manifestation, the use of combination therapies offers a promising approach to decrease systemic injury. By investing in such targeted interventions, cases of severe SARS-CoV-2 should decrease along with its associated long-term sequelae and thereby allow cancer patients to resume their treatments.

Pharmaceutics

Safety of Repeated Administration of Xenogeneic Human Apoptotic State (Allocetra-OTS) in Sprague Dawley Rats

Article

作者: Brami, Meital ; Hershkovitz, Oren ; Hershkovitz, Liat ; Sarig, Hadar ; Mevorach, Dror ; Amor-Baroukh, Veronique ; Reicher, Barak ; Levy, Ronnie ; Nyska, Abraham ; Souli, Einat ; Ankri, Chen

Apoptotic cells possess immunomodulatory effects that can be utilized to treat imbalanced immune conditions. Information on the preclinical safety of such treatment is sparse. In this study, the safety of apoptotic cells (Allocetra-OTS) was assessed in a GLP toxicological study on Sprague Dawley rats. Three doses of Allocetra-OTS or vehicle were administered intravenously (IV) for 3 consecutive days. Animals in the main study were sacrificed on day 4, while animals from the recovery groups were kept for 14 or 28 days. Allocetra-OTS was well tolerated, and no adverse effects were observed in terms of body weight, clinical signs, food consumption, or ophthalmologic observation. Thus, the No Observed Adverse Effect Level (NOAEL) dose was determined as the highest dose administered. An observed elevation in immune cells was suspected to be due to Allocetra-OTS, similarly to other clinical chemistry parameters; however, it was resolved in the recovery phases. Splenomegaly and dose-related extramedullary hematopoiesis (EMH) in the red pulp were observed, with no adverse events, and were considered to be a normal and expected reaction following the IV administration of cell-based therapies. In conclusion, under the conditions of this study, Allocetra-OTS was concluded to be safe, further supporting its potential candidacy for clinical studies.

118

项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的新闻（医药）

2026-05-18

·GlobeNewswire-Health Care

Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Enrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency (DKMA) approval received in April 2026 Nes-Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial is designed to evaluate the efficacy and safety of intra-articular injections of Allocetra™ in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, which is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. The trial is enrolling patients from clinical centers in the United States, Denmark and Poland. Key efficacy endpoints include changes from baseline of pain and physical function compared with placebo, measured at three- and six-month periods following treatment. Additional endpoints include changes in quality-of-life measures and functional mobility assessments. Oren Hershkovitz, Ph.D., CEO of Enlivex, commented, "Dosing the first patient in the United States marks a significant step in the execution of our global Phase 2b strategy for Allocetra™. The United States represents the largest clinical site network for this trial, and initiating enrollment there reflects the momentum we have built following FDA IND clearance and DKMA approval. Our Phase 1/2a data demonstrated a robust, durable, and clinically meaningful treatment effect in the patient population that is the center focus of this Phase 2b trial, and we believe that we are positioned to generate the data needed to move forward to the last stages of clinical development and offer a therapy that will address a significant unmet need for aging patients with this debilitating disease." About Enlivex (Nasdaq: ENLV) Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. About Knee Osteoarthritis Knee osteoarthritis (KOA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. There are currently no approved disease modifying therapies; treatment is largely limited to pain relief, intra-articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly 30% of the population, and about half of knee OA patients are 60 years and older. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFO Enlivex Ltd. shachar@enlivex.com

临床2期临床申请

2026-04-30

·GlobeNewswire-Health Care

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today reported that its treasury asset, the RAIN token, has been listed on the HTX cryptocurrency exchange, effective April 29, 2026. The listing marks an important step forward for RAIN, significantly increasing its accessibility, global reach, and token liquidity. HTX (formerly Huobi) is a leading global cryptocurrency exchange serving over 160 countries and is one of the most recognized platforms in the industry. HTX consistently ranks among the top 10 digital assets exchanges worldwide on platforms like CoinMarketCap and CoinGecko, reflecting its strong liquidity, large user base, and highly active trading environment. In 2025, HTX's annual cumulative trading volume reached approximately $3.3 trillion across over 700 assets, and its user base grew to over 59 million in Q1 2026. “RAIN is the primary asset of Enlivex’s digital asset treasury. We view major exchange listings as meaningful milestones that may support liquidity and market access for our treasury holdings,” said Oren Hershkovitz, CEO of Enlivex. Enlivex’s digital asset treasury strategy is focused on the acquisition of RAIN tokens. Recently, the Company announced its total RAIN holdings had increased to approximately 78.8 billion tokens with a total value of $567 million (as of April 27, 2026). RAIN serves as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. The protocol enables users globally to create, trade, and resolve markets tied to real-world events through a transparent and automated on-chain framework About Enlivex (Nasdaq: ENLV) Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN token, which is the token of the Rain protocol, a leading decentralized prediction markets infrastructure. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Ltd.shachar@enlivex.com

免疫疗法

2026-04-28

·GlobeNewswire-Health Care

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

New acquisitions from Rain Foundation underlines Enlivex’s disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that as of April 27, 2026, Enlivex’s total RAIN holdings increased to 78,819,756,062 tokens, which had a total value of $567 million1. Oren Hershkovitz, Ph.D, CEO of Enlivex, said, “Securing additional RAIN at a material discount to recent market prices reflects our disciplined treasury strategy that we believe may potentially create additional shareholder value. Our approach is supported by what we are seeing in the broader industry: growing Institutional appetite for exposure to prediction markets.” Enlivex’s most recent acquisitions of RAIN tokens were made via partial exercises of the Company’s option to acquire up to 272,121,212,121 RAIN tokens from the Rain Foundation, which independently oversees the decentralized prediction markets Rain protocol, at a purchase price of $0.0033 per RAIN token. The option’s expiration date is Dec. 31, 2027. The option’s exercise price represents an approximately 55% discount to RAIN’s closing price on April 27, 2026. About Enlivex (Nasdaq: ENLV) Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN token, which is the token of the Rain protocol, a leading decentralized prediction markets infrastructure. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Ltd.shachar@enlivex.com 1 Valuation is calculated using the closing price of the RAIN token as provided by https://coinmarketcap.com

并购免疫疗法

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床2期	以色列	Enlivex Ltd.	2024-01-26
局部晚期恶性实体瘤	临床2期	以色列	Enlivex Ltd.	2022-11-15
局部晚期恶性实体瘤	临床2期	西班牙	Enlivex Ltd.	2022-11-15
转移性肿瘤	临床2期	以色列	Enlivex Ltd.	2022-06-29
腹膜继发性恶性肿瘤	临床2期	以色列	Enlivex Ltd.	2022-06-29
急性呼吸窘迫综合征	临床2期	以色列	Enlivex Ltd.	2021-09-01
胆管炎	临床2期	比利时	Enlivex Ltd.	2020-11-30
胆管炎	临床2期	法国	Enlivex Ltd.	2020-11-30
胆管炎	临床2期	以色列	Enlivex Ltd.	2020-11-30
胆管炎	临床2期	荷兰	Enlivex Ltd.	2020-11-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06233474 (ENX-CL-05-001 \| ENXCL05001, GlobeNewswire) 人工标引	临床2期	膝关节炎	-	Allocetra	網糧築廠艱構選衊築鹹(廠繭願構繭選壓築蓋築) = 蓋膚築蓋選積遞鑰蓋壓衊築蓋簾網廠繭鏇鹽膚 (積窪膚壓壓襯糧製製廠 ) 更多	积极	2025-11-24
				Placebo	網糧築廠艱構選衊築鹹(廠繭願構繭選壓築蓋築) = 積衊積網獵襯願淵願夢衊築蓋簾網廠繭鏇鹽膚 (積窪膚壓壓襯糧製製廠 ) 更多
NCT06233474 (ENXCL05001, GlobeNewswire)	临床1/2期	骨关节炎 \| 膝关节炎	130	AllocetraOTS	餘醖廠鏇繭網積襯鹹艱(艱顧範獵鹽衊艱齋糧鏇): Difference (%) = 26 更多	积极	2025-08-18
				placebo
EULAR2025	临床1/2期	膝关节炎	15	AllocetraTM	繭製糧醖壓鑰蓋鬱襯簾(製繭製鏇製觸廠窪鏇願) = 鏇鏇鬱願壓構壓衊製選醖繭願鬱顧壓艱壓製廠 (齋範醖鬱淵餘鹹構顧積, 35.1 ~ 69.7) 更多	积极	2025-06-11
NCT06233474 (GlobeNewswire) 人工标引	临床1/2期	膝关节炎	12	Allocetra	艱鏇蓋糧範鬱醖艱壓範(構憲糧憲淵蓋顧築壓鏇) = 遞淵艱簾鏇齋網獵選獵簾遞鬱簾築遞鑰繭蓋鑰 (構積網構築獵醖齋簾簾 ) 更多	积极	2024-12-03
NCT06233474 (Biospace) 人工标引	临床1/2期	膝关节炎	9	Allocetra	鏇範遞構廠築鹹鹽構遞(鹽憲壓艱廠淵鑰鬱衊構) = 糧蓋簾齋齋鏇壓築鹹醖襯顧淵鹽選鑰廠鬱遞顧 (糧鑰蓋遞繭範衊遞鹽觸 ) 更多	积极	2024-06-17
NCT04612413 (GlobeNewswire) 人工标引	临床2期	脓毒症	-	Allocetra	構壓構鹹夢顧夢餘艱淵(築鹹襯獵遞齋糧顧窪觸) = 範衊鏇顧範夢簾願構選簾築鬱簾遞鹽範網築淵 (遞蓋淵齋齋繭窪淵範壓 ) 更多	积极	2024-04-11
NCT03925857 (P-SOFA-1, Pubmed \| Front Immunol) 人工标引	临床1期	脓毒症	10	Allocetra™-OTS	廠衊憲範網鏇簾鹹淵觸(醖範遞衊範鹹襯蓋範構) = No SAEs were reported. 繭繭範繭壓構顧鏇夢構 (構鹹鹽壓齋醖餘顧鹹膚 ) 更多	积极	2021-09-30
				historical controls
NCT04590053 (GlobeNewswire) 人工标引	临床2期	新型冠状病毒感染	16	Allocetra	網願鑰膚餘醖繭築鹹憲(窪觸艱鹹選鬱壓簾獵淵) = 糧築遞艱製顧築糧鏇簾齋範廠選製襯顧鏇壓齋 (餘廠顧衊遞壓膚網鏇遞 ) 更多	积极	2021-02-03
NCT03925857 (P-SOFA-1, GlobeNewswire) 人工标引	临床1期	脓毒症	47	Allocetra	窪艱夢糧顧顧選築選鏇(壓壓鬱遞襯網餘選鹹淵) = 簾築範餘鹹蓋繭鹽鏇鹹淵鬱憲醖膚範窪鬱製鏇 (鏇齋憲淵窪觸願簾壓選 ) 更多	积极	2020-03-18
				Standard of Care	觸廠齋鹹遞憲廠範選餘(鬱觸壓壓鹽鏇艱鬱醖築) = 醖餘鬱餘膚壓齋窪鑰醖築獵鏇壓壓範遞選範艱 (衊獵醖鬱鏇蓋築鹹衊願 ) 更多